Investigational drug · Phase 3
Brenipatide
Also called: LY3537031
Not approved by FDA. In 13 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
13
13 still active
All registered trials
14
Any phase or sponsor naming "Brenipatide"
First trial start
2025
Oct 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Brenipatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol Use Disorder
- Irritable Bowel Syndrome
- Depressive Disorder, Major
- Bipolar Disorder
- Major Depressive Disorder
- Diarrhea
- Smoking
- Pulmonary Disease, Chronic Obstructive
- Constipation
- Opioid Use Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Bipolar disorder · Opioid use disorder · Alcohol dependence · Irritable bowel syndrome · Psychiatry · Respiratory · Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Brenipatide" as an intervention, largest first.
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219966 · 1,100 participants (planned) · Start Oct 15, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 117 sites in all
- A Study of Brenipatide in Participants With Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219953 · 1,100 participants (planned) · Start Oct 16, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 115 sites in all
- A Study of Brenipatide in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07412756 · 1,000 participants (planned) · Start Feb 9, 2026 · Primary completion Feb 2028
Drug: Brenipatide; Placebo · For: Depressive Disorder, Major
Sites: Moorpark, California; Orange, California; New Haven, Connecticut · 180 sites in all
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07775300 · 1,000 participants (planned) · Start Aug 14, 2026 · Primary completion Dec 2028
Drug: Brenipatide; Placebo · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 170 sites in all
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07759245 · 606 participants (planned) · Start Aug 7, 2026 · Primary completion May 2028
Drug: Brenipatide; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Newport Beach, California; San Diego, California · 127 sites in all
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545759 · 531 participants (planned) · Start May 6, 2026 · Primary completion Sep 2027
Drug: LY3537031; Placebo · For: Irritable Bowel Syndrome; Diarrhea
Sites: Mesa, Arizona; Anaheim, California; Lancaster, California · 89 sites in all
- A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219173 · 531 participants (planned) · Start Oct 22, 2025 · Primary completion Apr 2028
Drug: Brenipatide; Brenipatide and 1 more · For: Asthma
Sites: Tempe, Arizona; Newport Beach, California; Northridge, California · 120 sites in all
- A Study of Brenipatide in Participants With Opioid Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07420283 · 465 participants (planned) · Start Feb 13, 2026 · Primary completion Mar 2028
Drug: Brenipatide; Placebo and 1 more · For: Opioid Use Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fountain Valley, California · 68 sites in all
- A Study of Brenipatide in Adult Participants With SchizophreniaPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07410507 · 450 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2027
Drug: Brenipatide; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Garden Grove, California · 101 sites in all
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07286175 · 400 participants (planned) · Start Nov 24, 2025 · Primary completion Nov 2027
Drug: Brenipatide; Placebo · For: Bipolar Disorder
Sites: Orange, California; New Haven, Connecticut; Hialeah, Florida · 87 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov.
Fagiolini A, Cuomo A · J Psychiatr Res 2026
Also in development for Alcohol Use Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.